Oritavancin for the Treatment of Daptomycin Nonsusceptible Vancomycin-Resistant Enterococci Osteomyelitis. Issue 2 (March 2018)

• Record Type: Journal Article
• Authors: Foster, Rachel A.; Philavong, Kingsavanh Paul; Weissman, Sharon; Tang, Xiaonan; Bookstaver, P. Brandon
• Is Part Of: Infectious diseases in clinical practice. Volume 26:Issue 2(2018:Mar.)
• Publication Date: 2018-03
• Subjects: daptomycin -- pharmacokinetics -- prosthesis -- oritavancin -- osteomyelitis -- vancomycin-resistant enterococci; Communicable diseases -- Periodicals; Communicable Diseases -- Periodicals; Communicable diseases; Periodicals; Periodicals; Electronic journals; 616.9
• DOI: 10.1097/IPC.0000000000000517
• Languages: English
• ISSNs: 1056-9103

Abstract

Abstract : Abstract: Vancomycin-resistant enterococci (VRE) are a growing cause of health care–associated infections globally, and limited treatment options exist for invasive VRE infections. Daptomycin is commonly used with modest success in the treatment of deep-seated infections secondary to VRE; however, there is concern for the emergence of daptomycin nonsusceptible VRE, especially during protracted courses, as required in osteomyelitis. We report the clinical and microbiologic success of a once-weekly, 6-week course of oritavancin with therapeutic drug monitoring in the treatment of daptomycin nonsusceptible VRE osteomyelitis secondary to prosthetic hip replacement. Our data suggest favorable pharmacokinetics and no treatment-related adverse events with once-weekly dosing. This report provides compelling information for future studies of prolonged oritavancin regimens in deep-seated infections. Abstract : The authors report the clinical and microbiologic success of once-weekly oritavancin in the treatment of daptomycinnonsusceptible vancomycin-resistant Enterococci osteomyelitis secondary to prosthetic hip replacement with no treatment-related adverse effects. These data suggest favorable pharmacokinetics with once-weekly dosing confirmed with therapeutic drug monitoring.